Tagged with Research

diagnostics Life Length was founded through the CNIO (Spanish National Cancer Research Center) combined with the support of the Botín Foundation, Matlin Associates and Dr. Maria Blasco’s work in telomeres. Stephen J. Matlin, CEO of Life Length, discusses the potential of the company’s diagnostic test to become a standard biomarker for…

cancer Manuel Hidalgo, director of the Centro Integral Oncológico Clara Campal (CIOCC), discusses the expansion of the private sector of hospitals in Spain and the latest developments that CIOCC has taken in the area of personalized medicine.   How has the quality of healthcare in Spain changed or evolved over the…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…

Gubelkian Jose Pereira Leal, Group Leader Head of the Bioinformatics Unit at Instituto Gulbenkian de Ciencia, discusses the institute’s unique selling point, stating that, “researchers will continue to come and stay here based on the excellence of research” that the country, and institute in particular, are currently experiencing.   Since its…

scienfitic output João Lobo Antunes, Founder of Institute of Molecular Medicine (IMM), Portugal gives his insights into Portugal’s strengths in science and technology, as well as his ambitions to grow IMM into one of the world’s leading institutes for genomics.   How would you rate Portugal’s scientific output nationwide? The scientific development…

Basic Research Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D throughout its vast geography. “Science powers commerce,” Canadian Prime Minister Stephen Harper remarked in 2010. In those three words, the prime minister summarizes a massive effort by various stakeholders to…

UAE Mohammed Zafrullah, VP & General Manager of GlaxoSmithKline (GSK) Pharmaceuticals, argues that the UAE, despite recent turmoil in the rest of the Middle East, is the perfect emerging country to do build a business in due to the many opportunities for innovation and growth.   To have a successful business,…

UAE Ahmad Tabari, Managing Director of Pharmax, gives his insight into the regions major challenges, why he thinks that, regardless of the amount of money the government invests, the problem of a small talent pool in the industry will not go away quickly or easily, and Pharmax’s strategy to overcome this…

UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late.   Our approach to…

Basic Research “If you look at the cuts in the public sector, the science budget has been relatively lightly touched. This sends a signal at a very high level that science, the knowledge economy, and the smart training of people are very important for our economic recovery,” says Mark Ferguson, Director General,…

Choice Pharma Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company discuss the merits of Taiwan for CROs, and how the environment is better today in Asia than in Europe for…

International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA) General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved in the discussions with the government on how to rectify this growing problem. During our interviews, general managers heading IRPMA…